Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 12/20 | 0.64 |
| ▸ | PARP11 | Q9NR21 | 9/20 | 0.64 |
| ▸ | PARP1 | P09874 | 5/20 | 0.56 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.56 |
| ▸ | TDP2 | O95551 | 1/20 | 0.54 |
| ▸ | GRM5 | P41594 | 5/20 | 0.54 |
| ▸ | F7 | P08709 | 1/20 | 0.50 |
| ▸ | F3 | P13726 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2995459 | 0.89 | PARP10 (0.51) | PARP10PARP11PARP1PDPK1TDP2 | |
| SCHEMBL793665 | 0.85 | PARP10 (0.64) | PARP10PARP11PARP1PDPK1TDP2 | |
| SCHEMBL1438853 | 0.81 | TDP2 (0.58) | PARP10PARP11PARP1TDP2GRM5 | |
| SCHEMBL1417646 | 0.78 | PARP10 (0.64) | PARP10PARP11PARP1PDPK1GRM5 | |
| SCHEMBL794160 | 0.78 | PARP10 (0.74) | PARP10PARP11PARP1PDPK1GRM5 | |
| SCHEMBL1315035 | 0.78 | PARP10 (0.74) | PARP10PARP11PARP1PDPK1GRM5 | |
| SCHEMBL6003822 | 0.78 | PARP10 (0.64) | PARP10PARP11PARP1PDPK1GRM5 | |
| SCHEMBL1002712 | 0.78 | PARP10 (1.00) | PARP10PARP11PARP1PDPK1TDP2 | |
| SCHEMBL15727824 | 0.78 | PARP10 (0.64) | PARP10PARP11PARP1PDPK1GRM5 | |
| SCHEMBL29978302 | 0.78 | PARP10 (1.00) | PARP10PARP11PARP1PDPK1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2598500-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS INC (US) | 2021-05-19 | — | — | EP | disclosed |
| WO-2012015972-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
| EP-1807393-B1 | DIARYLSULFONES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME (GB) | 2010-03-31 | — | — | EP | disclosed |
| US-20090170824-A1 | Diarylsulfones as 5-HT2A Antagonists | CASTRO PINEIRO JOSE LUIS | 2009-07-02 | — | — | US | disclosed |
| WO-2009036144-A1 | ISOQUINOLINYL AND ISOINDOLINYL DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20090069300-A1 | ISOQUINOLINYL AND ISOINDOLINYL DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069300-A1 | ISOQUINOLINYL AND ISOINDOLINYL DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069300-A1 | ISOQUINOLINYL AND ISOINDOLINYL DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-03-12 | — | — | US | disclosed |
| US-7468393-B2 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP & DOHME LTD. (GB) | 2008-12-23 | — | — | US | disclosed |
| US-20070203205-A1 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2007-08-30 | — | — | US | disclosed |
| EP-1807393-A1 | DIARYLSULFONES AS 5-HT2A ANTAGONISTS | Merck Sharp & Dohme Limited (GB) | 2007-07-18 | — | — | EP | disclosed |
| US-7217740-B2 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP AND DOHME | 2007-05-15 | — | — | US | disclosed |
| US-20060052445-A1 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2006-03-09 | — | — | US | disclosed |
| WO-2006021805-A1 | DIARYLSULFONES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069300-A1 | ISOQUINOLINYL AND ISOINDOLINYL DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | HRH4, HRH3, HRH2 | PARP10 2737/4885PARP11 3376/4885PARP1 4382/4885 |
| US-20070203205-A1 | Diarylsulfones as 5-HT2A antagonists | HTR2A, HTR2B, HTR1A | PARP10 2552/4885PARP11 3735/4885PARP1 4023/4885 |
| US-20060052445-A1 | Diarylsulfones as 5-HT2A antagonists | HTR2A, HTR2B, HTR1A | PARP10 2552/4885PARP11 3735/4885PARP1 4023/4885 |
| US-20090170824-A1 | Diarylsulfones as 5-HT2A Antagonists | HTR2A, HTR2B, HTR1A | PARP10 2552/4885PARP11 3735/4885PARP1 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.